Core Insights - The company reported a total operating revenue of 31.629 billion yuan for the year 2025, representing a year-on-year growth of 14.53% [1] - The net profit attributable to shareholders of the listed company reached 3.422 billion yuan, with a year-on-year increase of 1.60% [1] Strategic Focus - The company aims to adhere to a dual-driven strategy of "innovation + brand" to navigate a complex market environment [1] - The focus is on core treatment areas, expanding the research and development pipeline from multiple dimensions to uncover innovative value [1] - The company is committed to enhancing brand advantages, optimizing business layout, and forging a competitive edge across the entire industry chain to solidify its leading position in the industry [1] - The strategic goal is to strive to become a top enterprise in the industry [1]

Core Viewpoint - The company reported a solid performance in 2025, driven by its "innovation + brand" dual strategy, focusing on core treatment areas and expanding its R&D pipeline while optimizing its business layout [1][2][4] Financial Performance - In 2025, the company achieved an operating income of 31.629 billion yuan, a year-on-year increase of 14.53% - The total profit reached 4.860 billion yuan, up 5.81% year-on-year - The net profit attributable to shareholders was 3.422 billion yuan, reflecting a 1.60% increase year-on-year [1] Brand Strategy - The "innovation + brand" strategy has become a core factor for the company to navigate the pharmaceutical industry's adjustment cycle and maintain stable performance - The "999" core brand remains strong, with "999 Cold Medicine" capturing a 15% market share in the common cold medication market, an increase of 0.3 percentage points from the previous year [2] R&D Investment - R&D investment has been increasing annually, from 581 million yuan in 2020 to 953 million yuan in 2024 - In the first half of 2025, R&D investment reached 662 million yuan, a 68.99% year-on-year increase, with a total of 205 projects under research [3] Product Development - The company achieved significant milestones in 2025, including the approval of its first traditional Chinese medicine class 3.2 new drug, "999 Yiqi Qingfei Granules," which entered the national medical insurance drug list - The company has received five production approvals for class 3.1 traditional Chinese medicine formulations, maintaining an industry-leading position [3] M&A Strategy - The company has successfully implemented an external acquisition strategy, acquiring significant assets such as Kunming Pharmaceutical Group and Tianjin Tasly, which has helped expand its business footprint and create a "one body, two wings" business model [4][5] - The collaboration among the three listed companies has led to clear division of labor and synergistic development [4] Future Outlook - The company plans to deepen the "one body, two wings" strategy internally while continuously seeking acquisition targets in consumer health, medical health, and silver economy sectors externally - The focus will be on new products, new technologies, and high clinical value opportunities to support innovation and development strategies [6]

Core Viewpoint - China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. reported a revenue of 31.629 billion yuan for 2025, representing a year-on-year growth of 14.53%, and a net profit attributable to shareholders of 3.422 billion yuan, with a growth of 1.6% year-on-year [1] Group 1 - China Resources Sanjiu is a subsidiary of China Resources Pharmaceutical Group, holding an indirect stake of 63.22% [1] - The company aims to navigate a complex market environment by focusing on a dual strategy of "innovation + brand" [1] - The company is concentrating on core therapeutic areas and expanding its research and development pipeline to enhance innovation value [1] Group 2 - The company is optimizing its business layout to strengthen its brand advantages and build a competitive edge across the entire industry chain [1] - China Resources Sanjiu is committed to solidifying its position as an industry leader and is working towards the strategic goal of becoming a top enterprise in the sector [1]

Core Viewpoint - China Resources Pharmaceutical (03320) reported that China Resources Sanjiu (000999) achieved a total revenue of approximately 31.629 billion yuan in 2025, representing a year-on-year increase of 14.53% [1] - The net profit attributable to shareholders of the listed company was approximately 3.422 billion yuan, reflecting a year-on-year growth of 1.6% [1] - The basic earnings per share stood at 2.06 yuan [1] Group 1 - In 2025, China Resources Sanjiu faced challenges such as a decrease in the incidence of respiratory diseases like influenza and ongoing medical insurance cost control [1] - The company is committed to a strategic direction focused on "innovation + brand" dual-driven approach to navigate the complex market environment [1] - China Resources Sanjiu is concentrating on core therapeutic areas, expanding its research and development pipeline from multiple dimensions to uncover innovative value [1] Group 2 - The company is enhancing its brand advantages and continuously optimizing its business layout to forge a competitive edge across the entire industry chain [1] - China Resources Sanjiu aims to solidify its leading position in the industry and is making steady progress towards its strategic goal of becoming a top-tier enterprise in the sector [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 （於香港註冊成立的有限公司） （股份代號：3320） 公告 華潤三九截至2025年12月31日止年度的初步財務資料 I . 2025年主要財務資料及指標（未經審核） 單位：人民幣萬元 於2026年2月6日，華潤三九公佈其截至2025年12月31日止年度的未經審核初步 財務資料。 華潤三九醫藥股份有限公司（「華潤三九」）為一家於中華人民共和國註冊成立的公 司。華潤三九的股份於深圳證券交易所上市。截至本公告日期，華潤三九由華潤 醫藥集團有限公司（「本公司」，連同其附屬公司合稱為「本集團」）間接持有63.22 % 的權益，並為本公司的附屬公司。 – 1 – 於2026年2月6日，華潤三九公佈其截至2025年12月31日止年度（「本報告期」）的未 經審核初步財務資料（「華潤三九初步財務資料」）。下文載列華潤三九初步財務資 料的主要財務資料： | ...

Core Viewpoint - The company reported a total operating revenue of 31.629 billion yuan for 2025, representing a year-on-year increase of 14.53%, and a net profit of 3.422 billion yuan, with a year-on-year growth of 1.60% [1] Group 1 - The company is facing challenges such as a decrease in the incidence of respiratory diseases like influenza and ongoing medical insurance cost control [1] - The company aims to maintain a strategic direction focused on "innovation + brand" dual-driven approach to navigate the complex market environment [1] - The company is concentrating on core therapeutic areas, expanding its research and development pipeline, and enhancing its brand advantages to solidify its competitive edge across the entire industry chain [1] Group 2 - The company is committed to optimizing its business layout and reinforcing its leading position in the industry, with a strategic goal of becoming a top player in the sector [1]

Core Insights - The article highlights the transformation of China National Pharmaceutical Group (CR Sanjiu) from a company focused on a few OTC drugs to a comprehensive player in the pharmaceutical industry, emphasizing its "1+N" brand matrix that spans the entire health management lifecycle [1][2]. Group 1: Business Performance and Growth - CR Sanjiu aims to achieve a revenue of 27.6 billion yuan in 2024, representing a growth of over 102% compared to 2020 [2]. - The company has reported a compound annual growth rate (CAGR) of 23.6% in revenue and 24.5% in total profit over the past three years [2]. - R&D investment is projected to reach 950 million yuan in 2024, a 63.97% increase from 2020, with the number of R&D personnel exceeding 876, more than doubling since 2020 [2]. Group 2: Innovation and Product Development - CR Sanjiu has received four drug registration certificates and has five products in the application stage, leading the industry in this regard [3]. - The company has expanded its product offerings beyond its flagship "999" brand to include various health management products, such as "Tianhe" and "Auno" [3]. - The company is focused on maintaining long-term communication with consumers to enhance brand effect and keep the brand youthful [3]. Group 3: Strategic Partnerships and Market Positioning - CR Sanjiu is pursuing a strategy of mergers and acquisitions, positioning itself as the core entity while leveraging partnerships with Tianjin Tasly and Kunming Pharmaceutical Group [4][5]. - The three companies have distinct focuses: CR Sanjiu on consumer health, Tasly on prescription drugs, and Kunming on senior health, creating a synergistic effect [4]. - The company aims to capitalize on the increasing concentration in the retail pharmacy sector, expecting to gain market share through brand and scale advantages [4]. Group 4: Digital Transformation and Future Outlook - CR Sanjiu is committed to enhancing its production capabilities through digitalization and smart manufacturing, implementing the "Smart Sanjiu" strategy [6]. - The company is exploring the application of new technologies such as big data, AI, and robotics to improve efficiency and management [6]. - A stock incentive plan has been introduced to align management and core employees with the long-term value of the company, emphasizing the importance of talent in driving innovation [6].